

Resource Summary Report

Generated by [RRID](#) on Aug 3, 2026

CD133/1 Antibody, anti-human, pure

RRID:AB_615061

Type: Antibody

Proper Citation

Miltenyi Biotec Cat# 130-092-395, RRID:AB_615061

Antibody Information

URL: http://antibodyregistry.org/AB_615061

Proper Citation: Miltenyi Biotec Cat# 130-092-395, RRID:AB_615061

Target Antigen: CD133/1

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: Flow cytometry

Antigen Distribution: brain, endothelial cells, epithelial cells, heart, hematopoietic stem cells, kidney, liver, lung, pancreas, placenta, ES and iPS cells, red blood cells

Info: Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:TRUE, NonFunctional in human:FALSE, Functional in animal:FALSE, NonFunctional in animal:FALSE

Antibody Name: CD133/1 Antibody, anti-human, pure

Description: This monoclonal targets CD133/1

Target Organism: human

Clone ID: clone W6B3C1

Antibody ID: AB_615061

Vendor: Miltenyi Biotec

Catalog Number: 130-092-395

Record Creation Time: 20250820T023242+0000

Record Last Update: 20250820T135209+0000

Ratings and Alerts

- Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:TRUE, NonFunctional in human:FALSE, Functional in animal:FALSE, NonFunctional in animal:FALSE - NYU Langone's Center for Biospecimen Research and Development <https://med.nyu.edu/research/scientific-cores-shared-resources/center-biospecimen-research-development>

No alerts have been found for CD133/1 Antibody, anti-human, pure.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 4 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Wei Y, et al. (2023) Loss of α -1,2-mannosidase MAN1C1 promotes tumorigenesis of intrahepatic cholangiocarcinoma through enhancing CD133-FIP200 interaction. Cell reports, 42(12), 113588.

Hitomi M, et al. (2021) Asymmetric cell division promotes therapeutic resistance in glioblastoma stem cells. JCI insight, 6(3).

Chan LH, et al. (2018) PRMT6 Regulates RAS/RAF Binding and MEK/ERK-Mediated Cancer Stemness Activities in Hepatocellular Carcinoma through CRAF Methylation. Cell reports, 25(3), 690.

Chao OS, et al. (2017) The HDAC6 Inhibitor Tubacin Induces Release of CD133+ Extracellular Vesicles From Cancer Cells. Journal of cellular biochemistry, 118(12), 4414.